Israel’s Kamada Eyes $40m Sales As Alvotech Alliance Increases

Overall Portfolio Of 11 Products Includes Three From Two Unnamed Firms

 
• By Dean Rudge
Israel flag
Kamada’s typical focus is plasma-derived protein therapeutics • Source: Shutterstock

More from Biosimilars

More from Products